Bilateral segmental pulmonary embolism; Acute venous thromboembolism (VTE); Acute onset shortness of breath; Dyspnea on exertion; This literature-study case was reported in a literature article and describes the occurrence of PULMONARY EMBOLISM (Bilateral segmental pulmonary embolism), EMBOLISM VENOUS (Acute venous thromboembolism (VTE)), DYSPNOEA (Acute onset shortness of breath) and DYSPNOEA EXERTIONAL (Dyspnea on exertion) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PULMONARY EMBOLISM (Bilateral segmental pulmonary embolism) (seriousness criteria hospitalization and medically significant), EMBOLISM VENOUS (Acute venous thromboembolism (VTE)) (seriousness criteria hospitalization and medically significant), DYSPNOEA (Acute onset shortness of breath) (seriousness criterion hospitalization) and DYSPNOEA EXERTIONAL (Dyspnea on exertion) (seriousness criterion hospitalization). The patient was hospitalized for 3 days due to DYSPNOEA, DYSPNOEA EXERTIONAL, EMBOLISM VENOUS and PULMONARY EMBOLISM. The patient was treated with HEPARIN for Adverse event, at an unspecified dose and frequency and APIXABAN for Adverse event, at an unspecified dose and frequency. At the time of the report, PULMONARY EMBOLISM (Bilateral segmental pulmonary embolism), EMBOLISM VENOUS (Acute venous thromboembolism (VTE)), DYSPNOEA (Acute onset shortness of breath) and DYSPNOEA EXERTIONAL (Dyspnea on exertion) was resolving. Possible    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Brain natriuretic peptide: 99 pg/ml (Inconclusive) 99 pg/ml. On an unknown date, Computerised tomogram: abnormal (abnormal) revealed bilateral segmental pulmonary embolism. On an unknown date, Echocardiogram: abnormal (abnormal) mild/moderate right ventricular strain and 1.6 (Inconclusive) 1.6. On an unknown date, Haemoglobin: 14.8 gm/dl (Inconclusive) 14.8 gm/dl. On an unknown date, International normalised ratio: 1.0 (Inconclusive) 1.0. On an unknown date, Platelet count: 315 per mm3 (Inconclusive) 315 per mm3. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative. On an unknown date, Troponin: 0.28 ng/ml (Inconclusive) 0.28 ng/ml (normal <0.01). On an unknown date, Ultrasound Doppler: normal (normal) showed no deep venous thrombosis (DVT).     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered PULMONARY EMBOLISM (Bilateral segmental pulmonary embolism), EMBOLISM VENOUS (Acute venous thromboembolism (VTE)), DYSPNOEA (Acute onset shortness of breath) and DYSPNOEA EXERTIONAL (Dyspnea on exertion) to be possibly related.    Concomitant medications were not provided.  The patient was not infected with COVID-19. The RV/LV ratio of the patient was 1.8.  The patient used to take oral contraceptive pills (OCPs) for years prior to current admission to hospital. On presentation patient did not required supplemental oxygen. She was admitted to the intensive care unit (ICU) and monitored on a heparin drip. These symptoms improved with heparin (anticoagulant). The patient was discharged on hospital day 3 after being transitioned to apixaban (anticoagulant).  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded   This case was linked to MOD-2021-282440, MOD-2021-282441 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded